ea0029oc13.1 | Adrenal Basic | ICEECE2012
, Garcia E.
, Alusi G.
, Korbonits M.
, Grossman A.
Introduction: Since there is no completely effective therapy available for malignant phaeochromocytomas (PCCs) and paragangliomas, we have been investigating novel targeted therapies utilising one more benign (MPC) and one more malignant (MTT) PCC cell line. We have previously shown that the IGF1-receptor-inhibitor NVP-AEW541 led to compensatory ERK and mTORC1 up-regulation at suboptimal doses and that the dual PI3K/mTORC1-inhibitor NVP-BEZ235 also resulted in compensatory ERK...